LINQ II Insertable Cardiac Monitor, CareLink SmartSync LINQ II ICM Application

The LINQ II Insertable Cardiac Monitor (ICM) system is designed for long-term, continuous subcutaneous ECG monitoring to automatically detect and record cardiac arrhythmias, as well as enable patient-initiated recordings, in at-risk adult and pediatric populations. Utilizing a sapphire-based implant with titanium nitride-coated electrodes and a lithium battery, the system now incorporates the CareLink SmartSync LINQ II ICM Application to enhance its functionality and data management capabilities for improved arrhythmia diagnosis and management.

The LINQ II Insertable Cardiac Monitor (ICM) Model LNQ22 is a programmable device designed for continuous monitoring of a patient's subcutaneous electrocardiogram (ECG) and other physiological parameters. It is indicated for adult and pediatric patients (aged 2 years and older) who are at increased risk of cardiac arrhythmias or experience transient symptoms such as dizziness, palpitations, syncope, or chest pain suggestive of an arrhythmia. The system automatically records cardiac events when arrhythmias like tachyarrhythmia, bradyarrhythmia, pause, or atrial fibrillation are detected, and also allows patients to manually initiate recordings using the MyCareLink Heart App or a Patient Assistant during symptomatic episodes. The LINQ II ICM system includes accessories such as a tool kit, mobile manager, command libraries, and the AccuRhythm AI ECG Classification System, with a notable addition being the CareLink SmartSync LINQ II ICM Application. The LINQ II ICM features a small form factor with a hybrid sapphire substrate that forms part of its hermetic enclosure, integrating feedthroughs and providing a base for component attachment. Its antenna and sense electrodes are made of titanium foil coated with titanium nitride, laser-bonded to the sapphire, which is in turn bonded to a titanium battery cover. The device employs a lithium anode battery with a 167 mAh capacity. The primary technological update discussed involves the CareLink SmartSync LINQ II ICM Application Model D00U024. Design verification and validation, including software and system testing, were conducted specifically for this application to ensure it met design requirements and performance criteria under actual or simulated use conditions. The LINQ II ICM itself, including its operating principle of analyzing ventricular event timing to detect arrhythmias and its biocompatible materials (Sapphire, Titanium, Parylene, Titanium Nitride), remains unchanged from its predicate.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific "other physiological parameters" besides subcutaneous ECG does the LINQ II ICM monitor, and how do these contribute to arrhythmia detection or patient assessment?; How does the AccuRhythm AI ECG Classification System enhance the accuracy and efficiency of arrhythmia detection compared to previous algorithms or manual review?; What are the data security and privacy measures implemented within the CareLink SmartSync LINQ II ICM Application and the MyCareLink Heart App, especially concerning the transmission and storage of patient ECG data?; Are there comparative studies on the diagnostic yield and patient compliance between using the MyCareLink Heart App versus the dedicated Patient Assistant for manual symptom recording?; What is the expected battery longevity of the LINQ II ICM (167 mAh capacity) under typical continuous monitoring and recording conditions, and are there patient-specific factors that significantly impact it?